Antigen-Agnostic Combination Immunotherapy for Poorly Immunogenic Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer, particularly in poorly immunogenic tumors, rely on specific antigen knowledge and are not effective as standalone treatments, as they fail to overcome diverse immunosuppressive mechanisms and lack antigen specificity.
Innovation Solution
A combination immunotherapy using lymphokine-activated killer cells (LAKs), cytokine-induced killer cells (CIKs), γδ-T-cells, and tumor-specific T-cells (CTLs) with immune checkpoint targeting agents, Th-1 adjuvants, and IL-2 family cytokines, administered in a lymphodepleted state to enhance anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If single-agent immunotherapy is used, then treatment simplicity is maintained, but efficacy against diverse immunosuppressive mechanisms is insufficient
Solution Approach 1:
The patent combines multiple immunotherapeutic agents with different mechanisms of action into a single composition. The composition includes at least two agents from the group: checkpoint inhibitors, cytokines, cancer vaccines, adoptively transferred immune cells, oncolytic viruses, and immune modulators. This merging approach allows the treatment to address multiple immunosuppressive mechanisms simultaneously while maintaining relative treatment simplicity through unified administration.
2Measurement precision
If antigen-specific immunotherapy is used, then precision targeting is improved, but applicability to tumors with unknown antigens deteriorates
Solution Approach 1:
The patent creates a universal immunotherapy composition that does not require prior knowledge of tumor-specific antigens. The multi-agent formulation includes broad-spectrum agents such as checkpoint inhibitors that block multiple pathways, cytokines that activate general immune responses, and adoptively transferred immune cells that can recognize various tumor types. This universality allows the treatment to be applicable across different cancer types and patients regardless of their specific antigen profile.
3Reliability
If combination immunotherapy with multiple agents is used, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple immunotherapeutic agents into a single pharmaceutical composition that can be administered together. This approach maintains the therapeutic benefits of combination therapy while reducing the logistical complexity of administering multiple separate treatments. The composition includes agents with complementary mechanisms of action that work synergistically to overcome diverse immunosuppressive mechanisms in tumors.
4Adaptability or versatility
If antigen-agnostic approach is used, then versatility across tumor types is improved, but precision in targeting specific tumor antigens deteriorates
Solution Approach 1:
The patent employs a multi-functional composition designed to work across various tumor types without requiring antigen-specific customization. The inclusion of broad-spectrum agents such as checkpoint inhibitors, cytokines, and adoptively transferred immune cells provides universal applicability. The synergistic interaction between these agents compensates for the lack of antigen-specific precision, creating an effective treatment for poorly immunogenic tumors regardless of their specific antigen profile.
Data Source
AI summary
The present invention relates to a medicament for use in a method of preventing or treating cancer in a patient, wherein the medicament comprises at least two of the following populations of cells (i) to (iv): (i) a population of lymphokine-activated killer cells (LAKs), (ii) a population of cytokine-induced killer cells (CIKs), (iii) a population of γδ-T-cells, (iv) a population of tumor-specific T-cells (CTLs), wherein the population of cells in (i) to (iv) are derived from autologous cells from said patient or from allogeneic cells from a donor, and pharmaceutical composition, kit or kit-of-parts related thereto.